Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 11/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.44 |
| ▸ | MAPT | P10636 | 10/20 | 0.44 |
| ▸ | GAA | P10253 | 8/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663312 | 0.84 | MAPT (0.60) | MEN1KMT2AMAPTGAAKDM4E | |
| SCHEMBL118057 | 0.79 | MEN1 (0.57) | MAPKAPK2RPS6KA3CSNK2A1PLK3MEN1 | |
| SCHEMBL29449363 | 0.79 | MEN1 (0.57) | MAPKAPK2RPS6KA3CSNK2A1PLK3MEN1 | |
| SCHEMBL28307753 | 0.79 | MEN1 (0.58) | MAPKAPK2RPS6KA3CSNK2A1PLK3MEN1 | |
| SCHEMBL1192946 | 0.79 | F7 (0.47) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6621838 | 0.78 | MEN1 (0.55) | MAPKAPK2RPS6KA3CSNK2A1PLK3MEN1 | |
| SCHEMBL18782889 | 0.76 | MAPKAPK2 (0.49) | MAPKAPK2RPS6KA3CSNK2A1PLK3MEN1 | |
| SCHEMBL3035648 | 0.76 | MAPKAPK2 (0.49) | MAPKAPK2RPS6KA3CSNK2A1PLK3MEN1 | |
| SCHEMBL1925825 | 0.76 | KDM4E (0.57) | MAPKAPK2RPS6KA3CSNK2A1PLK3MEN1 | |
| SCHEMBL1143305 | 0.76 | MAPKAPK2 (0.49) | MAPKAPK2RPS6KA3CSNK2A1PLK3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4733300-A1 | NOVEL CHROMENE-BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2026-04-29 | — | — | EP | disclosed |
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM16A LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| WO-2024263007-A1 | NOVEL CHROMENE-BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2024-12-26 | — | — | WO | disclosed |
| CN-114269721-B | Compounds for the treatment of respiratory diseases | TMEM16A有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20240066023-A1 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | SISTEMA UNIVERSITARIO ANA G. MENDEZ, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11786520-B2 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | SISTEMA UNIV ANA G MENDEZ INC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11311531-B2 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | SISTEMA UNIV ANA G MENDEZ INC (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3983389-A1 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-114269721-A | Compounds for the treatment of respiratory diseases | TMEM16A有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220098167-A1 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | TMEM16A LTD (GB) | 2022-03-31 | — | — | US | disclosed |
| CN-103282034-A | Use of hematopoietic growth factor mimetics | LIGAND PHARM INC | 2013-09-04 | — | — | CN | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010036544-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2004092181-A9 | HETEROCYCLIC MCHR1 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-01-27 | — | — | WO | disclosed |
| US-5347008-A | Thio(cyclo) alkanepolycarboxylic acids containing heterocyclic substituents | CIBA-GEIGY CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| US-5152929-A | Corrosion inhibitors for water systems | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0129506-A2 | Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786520-B2 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | AHNAK, RECQL, NBAS | MAPKAPK2 3411/4885RPS6KA3 3594/4885CSNK2A1 2581/4885 |
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM109, SCN1A, SLC16A1 | MAPKAPK2 2372/4885RPS6KA3 2863/4885CSNK2A1 1731/4885 |
| US-11311531-B2 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | RECQL, AHNAK, NDUFS1 | MAPKAPK2 3466/4885RPS6KA3 3613/4885CSNK2A1 2398/4885 |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | MAPKAPK2 2051/4885RPS6KA3 2169/4885CSNK2A1 3249/4885 |
| US-20240066023-A1 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | AHNAK, RECQL, NBAS | MAPKAPK2 3411/4885RPS6KA3 3594/4885CSNK2A1 2581/4885 |
| US-20220098167-A1 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | TMEM109, SLC16A1, CFTR | MAPKAPK2 4643/4885RPS6KA3 2653/4885CSNK2A1 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.